Zentalis Pharmaceuticals (NASDAQ:ZNTL) Sees Strong Trading Volume
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Sees Strong Trading Volume
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) shares saw an uptick in trading volume on Wednesday . 32,512 shares were traded during mid-day trading, a decline of 95% from the previous session's volume of 637,692 shares.The stock last traded at $24.20 and had previously closed at $26.45.
纳斯达克(代码：ZNTL-GET Rating)的股票周三成交量有所上升。午盘成交量为32,512股，较前一交易日的637,692股下降95%。该股尾盘报24.20美元，此前收盘报26.45美元。
Analysts Set New Price Targets
分析师设定新的价格目标
A number of brokerages recently weighed in on ZNTL. SVB Leerink reduced their target price on Zentalis Pharmaceuticals from $67.00 to $42.00 and set an "outperform" rating on the stock in a report on Wednesday, August 10th. Morgan Stanley reduced their target price on Zentalis Pharmaceuticals from $95.00 to $60.00 and set an "overweight" rating on the stock in a report on Thursday, August 11th. Cowen began coverage on Zentalis Pharmaceuticals in a research report on Tuesday, July 12th. They issued an "outperform" rating on the stock. Cowen began coverage on Zentalis Pharmaceuticals in a research report on Tuesday, July 12th. They issued an "outperform" rating on the stock. Finally, Guggenheim cut their price objective on Zentalis Pharmaceuticals to $57.00 and set a "na" rating on the stock in a research report on Tuesday, May 17th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $61.38.
一些券商最近加入了ZNTL的行列。SVB Leerink在8月10日(周三)的一份报告中将Zentalis PharmPharmticals的目标价从67.00美元下调至42.00美元，并对该股设定了“跑赢大盘”的评级。摩根士丹利在8月11日(周四)的一份报告中将Zentalis PharmPharmticals的目标价从95.00美元下调至60.00美元，并对该股设定了“增持”评级。考恩在7月12日星期二的一份研究报告中开始报道Zentaris制药公司。他们对该股给予了“跑赢大盘”的评级。考恩在7月12日星期二的一份研究报告中开始报道Zentaris制药公司。他们对该股给予了“跑赢大盘”的评级。最后，古根海姆在5月17日星期二的一份研究报告中将其对Zentalis制药公司的目标价下调至57.00美元，并对该股设定了“NA”评级。根据MarketBeat.com的数据，9位分析师对该股的评级为买入，目前该股的普遍评级为“买入”，平均目标价为61.38美元。
Zentalis Pharmaceuticals Price Performance
Zentaris药品价格表现
The firm has a market capitalization of $1.37 billion, a PE ratio of -6.87 and a beta of 1.88. The stock has a 50-day moving average price of $28.58 and a 200-day moving average price of $30.83.
该公司的市值为13.7亿美元，市盈率为-6.87，贝塔系数为1.88。该股的50日移动均线价格为28.58美元，200日移动均线价格为30.83美元。
Insider Activity at Zentalis Pharmaceuticals
Zentalis制药公司的内幕活动
In related news, COO Kevin D. Bunker sold 1,710 shares of the business's stock in a transaction dated Wednesday, July 13th. The stock was sold at an average price of $30.02, for a total value of $51,334.20. Following the completion of the sale, the chief operating officer now directly owns 108,290 shares of the company's stock, valued at $3,250,865.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Zentalis Pharmaceuticals news, COO Kevin D. Bunker sold 5,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $30.00, for a total value of $150,000.00. Following the completion of the transaction, the chief operating officer now directly owns 100,000 shares in the company, valued at $3,000,000. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Kevin D. Bunker sold 1,710 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Wednesday, July 13th. The shares were sold at an average price of $30.02, for a total value of $51,334.20. Following the completion of the transaction, the chief operating officer now owns 108,290 shares of the company's stock, valued at $3,250,865.80. The disclosure for this sale can be found here. Insiders sold a total of 31,710 shares of company stock valued at $953,084 over the last three months. 19.90% of the stock is owned by insiders.
在相关新闻中，首席运营官凯文·D·邦克在一笔日期为7月13日星期三的交易中出售了1,710股该公司股票。这只股票的平均售价为30.02美元，总价值为51334.20美元。出售完成后，首席运营官现在直接拥有公司股票108,290股，价值3,250,865.80美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，用户可以通过以下链接访问该文件。在Zentalis制药公司的其他消息中，首席运营官Kevin D.Bunker在7月20日星期三的一笔交易中出售了5000股Zentalis制药公司的股票。这只股票的平均售价为30.00美元，总价值为15万美元。交易完成后，首席运营官现在直接拥有该公司10万股，价值300万美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，通过这个超级链接可以访问微博。此外，在7月13日星期三的一次交易中，首席运营官凯文·D·邦克出售了1,710股Zentalis制药公司的股票。这些股票的平均价格为30.02美元，总价值为51,334.20美元。交易完成后，首席运营官现在拥有该公司108,290股股票，价值3,250,865.80美元。此次拍卖的披露信息可在此处找到。过去三个月，内部人士总共出售了31,710股公司股票，价值953,084美元。19.90%的股份由内部人士持有。
Hedge Funds Weigh In On Zentalis Pharmaceuticals
对冲基金买入Zentalis制药公司股票
A number of hedge funds and other institutional investors have recently bought and sold shares of ZNTL. Matrix Capital Management Company LP boosted its stake in Zentalis Pharmaceuticals by 111.5% in the second quarter. Matrix Capital Management Company LP now owns 9,199,973 shares of the company's stock valued at $258,519,000 after acquiring an additional 4,850,694 shares during the period. Decheng Capital Management III Cayman LLC acquired a new position in shares of Zentalis Pharmaceuticals during the second quarter worth approximately $51,271,000. State Street Corp lifted its position in Zentalis Pharmaceuticals by 50.0% in the second quarter. State Street Corp now owns 3,119,734 shares of the company's stock worth $87,665,000 after purchasing an additional 1,039,294 shares during the period. FMR LLC lifted its position in Zentalis Pharmaceuticals by 15.3% in the second quarter. FMR LLC now owns 7,776,168 shares of the company's stock worth $218,510,000 after purchasing an additional 1,033,474 shares during the period. Finally, Perceptive Advisors LLC acquired a new stake in Zentalis Pharmaceuticals in the fourth quarter worth approximately $36,192,000.
一些对冲基金和其他机构投资者最近买卖了ZNTL的股票。MATRIX资本管理公司LP在第二季度增持了111.5%的Zentalis制药股份。在此期间，Matrix Capital Management Company LP增持了4,850,694股股票，目前拥有该公司9,199,973股股票，价值258,519,000美元。德成资本管理III开曼有限责任公司在第二季度收购了Zentalis制药公司的新股票，价值约51,271,000美元。道富集团在第二季度将其在Zentalis PharmPharmticals的头寸提高了50.0%。道富银行目前持有3,119,734股该公司股票，价值87,665,000美元，在此期间又购买了1,039,294股。FMR LLC在第二季度将其在Zentalis制药公司的头寸提高了15.3%。在此期间，FMR LLC又购买了1,033,474股，现在拥有7,776,168股该公司股票，价值218,510,000美元。最后，感知顾问公司在第四季度收购了Zentalis制药公司价值约36,192,000美元的新股份。
About Zentalis Pharmaceuticals
关于Zentaris制药公司
(Get Rating)
(获取评级)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
Zentalis制药公司是一家临床阶段的生物制药公司，专注于发现和开发用于治疗各种癌症的小分子疗法。它的主要候选产品包括WEE1的抑制剂ZN-c3，这是一种蛋白质酪氨酸激酶，正处于治疗晚期实体肿瘤的第二阶段临床试验；作为单一疗法治疗晚期实体肿瘤的第1/2阶段临床试验，以及正在进行的与铂耐药卵巢癌患者的联合化疗的1b阶段临床试验；以及肿瘤不可知的、可预测的生物标记物的第二阶段单一治疗试验。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- It's Time To Embrace Another 25% Decline In The S&P 500
- Four Cheap Stocks With Interesting Insider Activity
- Is Five Below Trying to Punch Too High?
- 免费获取StockNews.com关于Zentalis制药的研究报告(ZNTL)
- 随着收购传言的甚嚣尘上，Lyft能否成功？
- 健康饮料制造商Celsius能否超越其Monster竞争对手？
- 现在是时候接受标准普尔500指数再下跌25%的时候了
- 具有有趣内幕活动的四只廉价股票
- 下面的五个是不是打得太高了？
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得Zentaris制药日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Zentalis制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。